Eyepoint, Inc.
A biopharmaceutical company that treats serious eye diseases with tiny, long-lasting implants placed in the eye. Its Durasert technology delivers steady doses of medication over months, powering products like YUTIQ for uveitis and DEXYCU for inflammation after cataract surgery. Founded in 1987 and long known as pSivida Corporation, it renamed itself EyePoint in 2018 after buying Icon Bioscience — the name a nod to its single-minded focus on the eye.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 13G/APassive | 8.35% | 7.00M | Aug 14, 2026 |
| Bihua Chen | 13G/APassive | 8.35% | 7.00M | Aug 14, 2026 |
| Adage Capital Management, L.P. | 13GPassive | 5.71% | 4.79M | Aug 12, 2026 |
| Robert Atchinson | 13GPassive | 5.71% | 4.79M | Aug 12, 2026 |
| Phillip Gross | 13GPassive | 5.71% | 4.79M | Aug 12, 2026 |
| Vanguard Capital Management | 13GPassive | 5.03% | 4.22M | Jul 31, 2026 |
| BlackRock, Inc. | 13G/APassive | 7.7% | 6.43M | Jul 28, 2026 |
| Commodore Capital LP | 13GPassive | 5.1% | 4.25M | Jun 3, 2026 |
| Commodore Capital Master LP | 13GPassive | 5.1% | 4.25M | Jun 3, 2026 |
| Robert Egen Atkinson | 13GPassive | 5.1% | 4.25M | Jun 3, 2026 |